Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Inhaled immunotherapy shows promise for canine lung cancer
The study used interleukin-15 to reinvigorate the immune system.

Research could also have benefits for humans with the disease. 

US researchers have discovered that a protein naturally produced by the body could become a vital new immunotherapy drug in the fight against cancer.

Scientists at UC Davis and other institutions conducted a trial on 21 dogs with metastatic lung disease from osteosarcoma and melanoma. For 14 days, the dogs inhaled a mist containing interleukin-15 (IL-15) - a protein previously recognised for its immunotherapy properties.

The results, published in the Journal for ImmunoTherapy of Cancer, show that amplified concentrations of IL-15 can stimulate immune system defenses against some types of cancers in dogs. 

“No one previously had administered IL-15 as an inhaled treatment in dogs to deliver it directly to the site of the cancer,” explained Dr Rober Canter, a surgical oncologist at UC Davis Comprehensive Cancer Center. “We came up with that idea as a means of reducing exposure to the rest of the body, in order to improve the benefit-risk ratio, to improve the immune stimulating effects, and to reduce toxicity.”

“In this study, we used interleukin-15 to reinvigorate the immune system to make it recognize the cancer cells that had evaded the immune system and eliminate them.”

In the first-of-its-kind trial, the dogs began to show significant responses to the protein two weeks after they begain inhaling the mist. 

In two dogs, tumours shrank dramatically – including one that went into complete remission for more than a year. Furthermore, cancer that had been growing rapidly in five other dogs stabilised for several months - with the overall response rate being close to 40 per cent.

While more research is yet to be carried out, the team hopes that its findings will also benefit humans with advanced metastatic cancer.

“As part of our comparative oncology research, we are strong advocates of clinical trials in companion dogs, especially for immunotherapy, as a way to speed bench-to-bedside translation,” added Dr Canter. “The cancers that afflict dogs, including sarcomas, brain tumors, lymphoma and melanoma, are incredibly similar to cancers that humans develop.” 

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.